Download PDF
Thromb Haemost 2016; 116(05): 958-966
DOI: 10.1160/TH16-03-0185
Stroke, Systemic or Venous Thromboembolism
Schattauer GmbH

The risk of venous thromboembolism in patients with hepatitis C

A systematic review and meta-analysis
Pasquale Ambrosino
1   Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
,
Luciano Tarantino
2   Department of Surgery, Interventional Hepatology Unit, Andrea Tortora Hospital, Pagani, Italy
,
Livio Criscuolo
1   Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
,
Aurelio Nasto
3   Department of Surgery, Unit of General Surgery and Oncology, Andrea Tortora Hospital, Pagani, Italy
,
Aldo Celentano
1   Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
,
Matteo Nicola Dario Di Minno
4   Department of Advanced Biomedical Sciences, Division of Cardiology, Federico II University, Naples, Italy
5   Centro Cardiologico Monzino, IRCCS, Milan, Italy
› Author Affiliations
Further Information

Publication History

Received: 04 March 2016

Accepted after major revision: 07 June 2016

Publication Date:
30 November 2017 (online)

    Permissions and Reprints

Summary

Some studies suggest that patients with hepatitis C virus (HCV) infection have an increased risk of deep venous thrombosis (DVT) and pulmonary embolism (PE). Unfortunately, available data on this association are contrasting. A systematic review and meta-analysis of literature studies was performed to evaluate the risk of venous thromboembolism (VTE) associated with HCV. Studies reporting on VTE risk associated with HCV were systematically searched in the PubMed, Web of Science, Scopus and EMBASE databases. Six studies (10 data-sets) showed a significantly increased VTE risk in 100,364 HCV patients as compared with 8,471,176 uninfected controls (odds ratio [OR]: 1.900; 95 % confidence interval [CI]: 1.406, 2.570; p<0.0001). These results were confirmed when specifically considering the risk of DVT (6 studies, OR: 1.918; 95 %CI: 1.351, 2.723; p<0.0001), whereas a trend towards an increased risk of PE was documented in HCV patients (4 studies, OR: 1.811; 95 %CI: 0.895, 3.663; p=0.099). The increased VTE risk associated with HCV infection was consistently confirmed when analysing four studies reporting adjusted risk estimates (OR: 1.876; 95 %CI: 1.326, 2.654; P<0.0001), and after excluding studies specifically enrolling populations exposed to transient risk factors for VTE (4 studies, OR: 1.493; 95 %CI: 1.167, 1.910; p=0.001). Meta-regression models suggested that age and male gender may significantly impact on the risk of VTE associated with HCV-positivity. Results of our metaanalysis suggest that HCV-infected subjects may exhibit an increased risk of VTE. However, further high quality studies are needed to extend and confirm our findings.

Supplementary Material to this article is available online at www.thrombosis-online.com.

Keywords

Hepatitis C - viral hepatitis - deep venous thrombosis - pulmonary embolism - venous thromboembolism

 

  • References

  • 1 Wasley A, Alter MJ. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000; 20: 1e16.
    PubMedGoogle Scholar
  • 2 Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001; 345: 41-52.
    CrossrefPubMedGoogle Scholar
  • 3 Conry-Cantilena C, VanRaden M, Gibble J. et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 1996; 334: 1691-1696.
    CrossrefPubMedGoogle Scholar
  • 4 Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36: S35-S46.
    PubMedGoogle Scholar
  • 5 Zignego AL, Craxi A. Extrahepatic manifestations of hepatitis C virus infection. Clin Liver Dis 2008; 12: 611-636.
    CrossrefPubMedGoogle Scholar
  • 6 Khattab MA, Eslam M, Alavian SM. Hepatitis C virus as a multifaceted disease: a simple and updated approach for extrahepatic manifestations of hepatitis C virus infection. Hepat Mon 2010; 10: 258e69.
    PubMedGoogle Scholar
  • 7 Durante-Mangoni E, Iardino P, Resse M. et al. Silent celiac disease in chronic hepatitis C: impact of interferon treatment on the disease onset and clinical outcome. J Clin Gastroenterol 2004; 38: 901e5.
    PubMedGoogle Scholar
  • 8 Goeijenbier M, van Wissen M, van de Weg C. et al. Review: Viral infections and mechanisms of thrombosis and bleeding. J Med Virol 2012; 84: 1680-1696.
    CrossrefPubMedGoogle Scholar
  • 9 Negro F. Facts and fictions of HCV and comorbidities: steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol 2014; 61: S69-78.
    CrossrefPubMedGoogle Scholar
  • 10 Enger C, Forssen UM, Bennett D. et al. Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: a matched-cohort study. Adv Ther 2014; 31: 891-903.
    CrossrefPubMedGoogle Scholar
  • 11 Petta S, Macaluso FS, Craxì A. Cardiovascular diseases and HCV infection: a simple association or more?. Gut 2014; 63: 369-375.
    CrossrefPubMedGoogle Scholar
  • 12 Petta S, Maida M, Macaluso FS. et al. Hepatitis C Virus Infection Is Associated With Increased Cardiovascular Mortality: A Meta-Analysis of Observational Studies. Gastroenterology 2016; 150: 145-155 e4.
    CrossrefPubMedGoogle Scholar
  • 13 He Huang, Kang R, Zhao Z. Hepatitis C virus infection and risk of stroke: a systematic review and meta-analysis. PLoS One 2013; 08: e81305.
    CrossrefPubMedGoogle Scholar
  • 14 RostamiJalilian M, Omid Ghaemi M. et al. Relationship of hepatitis B and C with deep vein thrombosis in IV drug abusers. J Mil Med 2006; 08: 78-81.
    PubMedGoogle Scholar
  • 15 Wang CC, Chang CT, Lin CL. et al. Hepatitis C virus infection associated with an increased risk of deep vein thrombosis: a population-based cohort study. Medicine 2015; 94: e1585.
    CrossrefPubMedGoogle Scholar
  • 16 Galli L, Gerdes VE, Guasti L. et al. Thrombosis Associated with Viral Hepatitis. J Clin Transl Hepatol 2014; 02: 234-239.
    PubMedGoogle Scholar
  • 17 Moher D, Liberati A, Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLOS Med 2009; 06: e1000097.
    CrossrefPubMedGoogle Scholar
  • 18 Juni P, Witschi A, Bloch R. et al. The hazards of scoring the quality of clinical trials for meta-analysis. J Am Med Assoc 1999; 282: 1054-1060.
    CrossrefPubMedGoogle Scholar
  • 19 Higgins JP, Thompson SG, Deeks JJ. et al. Measuring inconsistency in meta-analyses. Br Med J 2003; 327: 557-560.
    CrossrefPubMedGoogle Scholar
  • 20 Sterne JA, Egger M, Smith GD. Systematic reviews in health care: investigating and dealing with publication and other biases in meta-analysis. Br Med J 2001; 323: 101-105.
    CrossrefPubMedGoogle Scholar
  • 21 Duval S, Tweedie R. Trim and fill: A simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 2000; 56: 455-463.
    CrossrefPubMedGoogle Scholar
  • 22 Ahmed S, Mehta V, Vendetti N. et al. Risk of venous thromboembolism (VTE) in patients with chronic hepatitis C (CHC). Pharmacoepidemiol Drug Saf 2012; 21: 1-481.
    PubMedGoogle Scholar
  • 23 Best MJ, Buller LT, Klika AK. et al. Increase in perioperative complications following primary total hip and knee arthroplasty in patients with hepatitis C without cirrhosis. J Arthroplasty 2015; 30: 663-668.
    CrossrefPubMedGoogle Scholar
  • 24 El Bokl MA, Shawky A, Riad GS. Abdel et al. Procoagulant versus anticoagulant factors in cirrhotic patients. Arab J Gastroenterol 2014; 15: 123-129.
    CrossrefPubMedGoogle Scholar
  • 25 Qi X, Ren W, Guo X. et al. Epidemiology of venous thromboembolism in patients with liver diseases: a systematic review and meta-analysis. Intern Emerg Med 2015; 10: 205-217.
    CrossrefPubMedGoogle Scholar
  • 26 Ha NB, Regal RE. Anticoagulation in Patients With Cirrhosis: Caught Between a Rock-Liver and a Hard Place. Ann Pharmacother 2016; 50: 402-409.
    CrossrefPubMedGoogle Scholar
  • 27 Engbers MJ, van Hylckama Vlieg A. et al. Venous thrombosis in the elderly: incidence, risk factors and risk groups. J Thromb Haemost 2010; 08: 2105-2112.
    CrossrefPubMedGoogle Scholar
  • 28 Roach RE, Lijfering WM, Tait RC. et al. Sex difference in the risk of recurrent venous thrombosis: a detailed analysis in four European cohorts. J Thromb Haemost 2015; 13: 1815-1822.
    CrossrefPubMedGoogle Scholar
  • 29 Zampino R, Marrone A, Restivo L. et al. Chronic HCV infection and inflammation: clinical impact on hepatic and extra-hepatic manifestations. World J Hepatol 2013; 05: 528-540.
    CrossrefPubMedGoogle Scholar
  • 30 Lesmana CR, Inggriani S, Cahyadinata L. et al. Deep vein thrombosis in patients with advanced liver cirrhosis: a rare condition?. Hepatol Int 2010; 04: 433-438.
    CrossrefPubMedGoogle Scholar
  • 31 Tripodi A, Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147-156.
    CrossrefPubMedGoogle Scholar
  • 32 Northup PG, McMahon MM, Ruhl AP. et al. Coagulopathy does not fully protect hospitalized cirrhosis patients from peripheral venous thromboembolism. Am J Gastroenterol 2006; 101: 1524-1528.
    CrossrefPubMedGoogle Scholar
  • 33 Lisman T, Porte RJ. Rebalanced hemostasis in patients with liver disease: evidence and clinical consequences. Blood 2010; 116: 878-885.
    CrossrefPubMedGoogle Scholar
  • 34 Ambrosino P, Lupoli R, Tarantino P. et al. Viral hepatitis and anti-phospholipid antibodies positivity: A systematic review and meta-analysis. Dig Liver Dis 2015; 47: 478-487.
    CrossrefPubMedGoogle Scholar
  • 35 Ambrosino P, Lupoli R, Spadarella G. et al. Autoimmune liver diseases and antiphospholipid antibodies positivity: a meta-analysis of literature studies. J Gastrointestin Liver Dis 2015; 24: 25-34.
    PubMedGoogle Scholar
  • 36 Yadav D, Hertan HI, Schweitzer P. et al. Serum and liver micronutrient antioxidants and serum oxidative stress in patients with chronic hepatitis C. Am J Gastroenterol 2002; 97: 2634-2639.
    CrossrefPubMedGoogle Scholar
  • 37 Jacobson Brown PM, Neuman MG. Immunopathogenesis of hepatitis C viral infection: Th1/Th2 responses and the role of cytokines. Clin Biochem 2001; 34: 167-171.
    CrossrefPubMedGoogle Scholar
  • 38 Oliveira CP, Kappel CR, Siqueira ER. et al. Effects of hepatitis C virus on cardiovascular risk in infected patients: a comparative study. Int J Cardiol 2013; 164: 221-226.
    CrossrefPubMedGoogle Scholar
  • 39 Opal SM. Interactions between coagulation and inflammation. Scand J Infect Dis 2003; 35: 545-554.
    CrossrefPubMedGoogle Scholar
  • 40 Tarantino L, Ambrosino P, Di Minno MN. Contrast-enhanced ultrasound in differentiating malignant from benign portal vein thrombosis in hepatocellular carcinoma. World J Gastroenterol 2015; 21: 9457-9460.
    CrossrefPubMedGoogle Scholar
  • 41 Kralj D, Virović Jukić L. et al. Hepatitis C Virus, Insulin Resistance, and Steatosis. J Clin Transl Hepatol 2016; 04: 66-75.
    PubMedGoogle Scholar